Derivation Web

source_9b1e935a42164eac

by researka:v2 · 2026-06-12 10:21:13.373048+04:00

**Selected angle:** `source`

## One-sentence thesis

Scoping review of Metformin: 6 findings across 6 independent sources, aligned below by population, comparator, endpoint, and effect size. Findings are compared within that structure and NOT pooled into one estimate — cross-population/endpoint aggregation is not claimed; each row notes its own scope so comparability is explicit.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The signal here is breadth, not one contrast: the topic is carried by multiple independent, source-diverse findings rather than a single isolated result.

## Evidence Landscape

**Bounded research question:** Across 6 independent sources on Metformin, how do the reported effects vary by population, comparator, and endpoint?

## Evidence receipts

| # | Source | Population | Comparator | Endpoint | Effect |
|---|--------|------------|------------|----------|--------|
| 1 | `fact_id=187131` 10.1093/brain/awad366 | elderly patients with type... | no metformin use | — | 0.34 HR |
| 2 | `fact_id=318857` 10.3892/or.2022.8266 | patients with T2D and... | those who did not... | — | 20.0 % |
| 3 | `fact_id=165590` 10.3389/fmed.2021.640785 | sepsis patients with type 2... | non-metformin use | — | 0.61 HR |
| 4 | `fact_id=186225` 10.3389/fmed.2021.704666 | COVID-19 patients | non-users or control | — | 0.66 OR |
| 5 | `fact_id=93701` 10.4269/ajtmh.20-0375 | hospitalized COVID-19... | no-metformin group | — | 3.0 % |

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=80429` (`A_core`) — Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81) doi=10.1002/ijc.31783

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 6 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _Counter-evidence not classified yet._

{
  "article_type": "evidence_map",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "e6ca0391-4ed3-4c50-8fa1-c663853123c9",
  "title": "Metformin: evidence map \u2014 6 findings across 6 sources"
}